semaglutide cardiovascular risk outcomes news Population‐level impact of semaglutide 2.4 mg in patients with obesity A trial emulation in Nature

Description

There are interesting relationships that people with eating disorders have with various drugs and using them for particular reasons to drive their eating disorder behaviors and symptoms and in ways that are slightly different than the traditional addictive processes of using substances to achieve euphoria and becoming addicted and entering that sort of cycle. Peiper and Levinson also want to investigate if there are addictive components to taking something to alter weight

Omzo's consumer-facing materials do not name a specific medical group entity as of June 2026

Vomiting on Ozempic may also be a sign of a more serious condition

By naturally lowering calorie intake and improving blood sugar regulation, GLP-1s help support steady, sustainable fat loss when combined with healthy lifestyle habits